Business
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results
Revenues increased 14% in Q4 2024 compared to Q4 2023Gross profit margin improved 3% in FY 2024 compared to FY 2023Net loss improved 18% in Q4 2024 compared
About this update from Sonoma Pharmaceuticals, Inc.
[{"type":"text","content":"Revenues increased 14% in Q4 2024 compared to Q4 2023Gross profit margin improved 3% in FY 2024 compared to FY 2023Net loss improved 18% in Q4 2024 compared to Q4 2023, and 6% in FY 2024 compared to FY 2023BOULDER, CO / ACCESSWIRE / June 17, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2024 and the fourth quarter ended March 31, 2024.\"We are pleased to report continued product-related growth and reduced cash burn in both our fourth quarter and fiscal year 2024 results. Fueled by significant worldwide demand for our technology, we've expanded our revenue channels and developed new products over the past year,\" said Amy Trombly, CEO of Sonoma. \"We remain focused on control of expenses and identifying new growth opportunities as we drive the business toward profitability.\"Recent Business HighlightsSonoma continued to grow its distribution network by introducing new products, entering into new partnerships, and working with existing partners to expand our markets:On May 9, 2024, we announced expansion of our MicrocynAH® animal health care products in the Menards® chain of home improvement stores in the United States, through our partner Compana Pet Brands.On April 9, 2024, we announced expansion of our Microcyn Negative Pressure Wound Therapy Solution products line, now available in 250mL, 450mL and 990mL sizes to meet the diverse needs of healthcare professionals and patients.On January 23, 2024, we launched LumacynTM Clarifying Mist, a new direct-to-consumer skincare product, in the United States. Lumacyn is an all-natural daily toner formulated with Microcyn technology to soothe the skin, reduce redness and irritation, and manage blemishes by reducing infection.A 2024 publication in the journal Neurourology and Urodynamics highlighted the potential for Microdox®, distributed by our partner, Te Arai BioFarma Ltd, in Australia and New Zealand, in the management of urinary tract infections, or UTIs, in children with neurogenic or non‐neurogenic bladder dysfunction.Results for the Quarte...